Biocryst Pharmaceuticals (BCRX) Return on Equity (2011 - 2026)

Biocryst Pharmaceuticals has reported Return on Equity for 16 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.01%, down 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.01% in Q1 2022, with the low at 0.01% in Q4 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2023.
• Annual changes were most pronounced in 2022 — Return on Equity fell 3 bps — and 2026, when it gained 1 bps.
• Biocryst Pharmaceuticals' Return on Equity stood at 0.01% in 2022, then plunged by 43 bps to 0.01% in 2023, then sank by 64 bps to 0.0% in 2024, then tumbled by 653 bps to 0.01% in 2025, then surged by 231 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.